Experience with Biosimilar Infliximab (Remsima®) in Norway

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Real-Life Evaluations of Compliance with Mandatory Drug Safety Monitoring Exemplified with Tolcapone in Parkinson’s Disease

By  

European Neurology, Vol. 60, Iss. 3, 2008-07 ,pp. : 122-126

Karger

Access to resources Recommend Favorite

Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

By Hayat Sawsan Johar   Uppal Sukhbir Singh  

Modern Rheumatology, Vol. 17, Iss. 2, 2007-04 ,pp. : 174-177

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis

By Hayat Sawsan   Uppal Sukhbir   Narayanan Nampoory M.   Johny Kaivilayil   Gupta Ramkumar   Al-Oun Mohammed  

Clinical Rheumatology, Vol. 26, Iss. 6, 2007-06 ,pp. : 973-975

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement

By Rejón E   Giménez MD   Mayordomo L   Rodríguez S   González MP   Marenco JL  

Scandinavian Journal of Rheumatology, Vol. 33, Iss. 5, 2004-10 ,pp. : 323-326

Informa Healthcare

Access to resources Recommend Favorite